Peringatan Keamanan

ORAL (LD50): Acute: 700 mg/kg Mouse. 1100 mg/kg Rat. 4000 mg/kg Dog.

Formic acid

DB01942

small molecule experimental investigational

Deskripsi

Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. It is commonly used as a preservative and antibacterial agent in livestock feed.

Struktur Molekul 2D

Berat 46.0254
Wujud liquid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Formic acid is readily metabolized and eliminated by the body.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

92 Data
Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Formic acid.
Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Formic acid.
Menadione Menadione may increase the thrombogenic activities of Formic acid.
Tranexamic acid Tranexamic acid may increase the thrombogenic activities of Formic acid.
Aprotinin Aprotinin may increase the thrombogenic activities of Formic acid.
Hydrogen peroxide Hydrogen peroxide may increase the thrombogenic activities of Formic acid.
Aminomethylbenzoic acid Aminomethylbenzoic acid may increase the thrombogenic activities of Formic acid.
Camostat Camostat may increase the thrombogenic activities of Formic acid.
Menadione bisulfite Menadione bisulfite may increase the thrombogenic activities of Formic acid.
Monteplase The therapeutic efficacy of Formic acid can be decreased when used in combination with Monteplase.
Lepirudin The therapeutic efficacy of Formic acid can be decreased when used in combination with Lepirudin.
Bivalirudin The therapeutic efficacy of Formic acid can be decreased when used in combination with Bivalirudin.
Alteplase The therapeutic efficacy of Formic acid can be decreased when used in combination with Alteplase.
Urokinase The therapeutic efficacy of Formic acid can be decreased when used in combination with Urokinase.
Reteplase The therapeutic efficacy of Formic acid can be decreased when used in combination with Reteplase.
Anistreplase The therapeutic efficacy of Formic acid can be decreased when used in combination with Anistreplase.
Tenecteplase The therapeutic efficacy of Formic acid can be decreased when used in combination with Tenecteplase.
Abciximab The therapeutic efficacy of Formic acid can be decreased when used in combination with Abciximab.
Drotrecogin alfa The therapeutic efficacy of Formic acid can be decreased when used in combination with Drotrecogin alfa.
Streptokinase The therapeutic efficacy of Formic acid can be decreased when used in combination with Streptokinase.
Dicoumarol The therapeutic efficacy of Formic acid can be decreased when used in combination with Dicoumarol.
Argatroban The therapeutic efficacy of Formic acid can be decreased when used in combination with Argatroban.
Ardeparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Ardeparin.
Phenindione The therapeutic efficacy of Formic acid can be decreased when used in combination with Phenindione.
Fondaparinux The therapeutic efficacy of Formic acid can be decreased when used in combination with Fondaparinux.
Warfarin The therapeutic efficacy of Formic acid can be decreased when used in combination with Warfarin.
Pentosan polysulfate The therapeutic efficacy of Formic acid can be decreased when used in combination with Pentosan polysulfate.
Phenprocoumon The therapeutic efficacy of Formic acid can be decreased when used in combination with Phenprocoumon.
Dipyridamole The therapeutic efficacy of Formic acid can be decreased when used in combination with Dipyridamole.
Heparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Heparin.
Enoxaparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Enoxaparin.
Epoprostenol The therapeutic efficacy of Formic acid can be decreased when used in combination with Epoprostenol.
Acenocoumarol The therapeutic efficacy of Formic acid can be decreased when used in combination with Acenocoumarol.
4-hydroxycoumarin The therapeutic efficacy of Formic acid can be decreased when used in combination with 4-hydroxycoumarin.
Coumarin The therapeutic efficacy of Formic acid can be decreased when used in combination with Coumarin.
Ximelagatran The therapeutic efficacy of Formic acid can be decreased when used in combination with Ximelagatran.
Desmoteplase The therapeutic efficacy of Formic acid can be decreased when used in combination with Desmoteplase.
Defibrotide The therapeutic efficacy of Formic acid can be decreased when used in combination with Defibrotide.
Ancrod The therapeutic efficacy of Formic acid can be decreased when used in combination with Ancrod.
Beraprost The therapeutic efficacy of Formic acid can be decreased when used in combination with Beraprost.
Prasugrel The therapeutic efficacy of Formic acid can be decreased when used in combination with Prasugrel.
Rivaroxaban The therapeutic efficacy of Formic acid can be decreased when used in combination with Rivaroxaban.
Sulodexide The therapeutic efficacy of Formic acid can be decreased when used in combination with Sulodexide.
Idraparinux The therapeutic efficacy of Formic acid can be decreased when used in combination with Idraparinux.
Cangrelor The therapeutic efficacy of Formic acid can be decreased when used in combination with Cangrelor.
Astaxanthin The therapeutic efficacy of Formic acid can be decreased when used in combination with Astaxanthin.
Apixaban The therapeutic efficacy of Formic acid can be decreased when used in combination with Apixaban.
Otamixaban The therapeutic efficacy of Formic acid can be decreased when used in combination with Otamixaban.
Amediplase The therapeutic efficacy of Formic acid can be decreased when used in combination with Amediplase.
Dabigatran etexilate The therapeutic efficacy of Formic acid can be decreased when used in combination with Dabigatran etexilate.
Danaparoid The therapeutic efficacy of Formic acid can be decreased when used in combination with Danaparoid.
Dalteparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Dalteparin.
Tinzaparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Tinzaparin.
(R)-warfarin The therapeutic efficacy of Formic acid can be decreased when used in combination with (R)-warfarin.
Ethyl biscoumacetate The therapeutic efficacy of Formic acid can be decreased when used in combination with Ethyl biscoumacetate.
Nadroparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Nadroparin.
Triflusal The therapeutic efficacy of Formic acid can be decreased when used in combination with Triflusal.
Ticagrelor The therapeutic efficacy of Formic acid can be decreased when used in combination with Ticagrelor.
Ditazole The therapeutic efficacy of Formic acid can be decreased when used in combination with Ditazole.
Vorapaxar The therapeutic efficacy of Formic acid can be decreased when used in combination with Vorapaxar.
Edoxaban The therapeutic efficacy of Formic acid can be decreased when used in combination with Edoxaban.
Sodium citrate The therapeutic efficacy of Formic acid can be decreased when used in combination with Sodium citrate.
Dextran The therapeutic efficacy of Formic acid can be decreased when used in combination with Dextran.
Bemiparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Bemiparin.
Parnaparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Parnaparin.
Desirudin The therapeutic efficacy of Formic acid can be decreased when used in combination with Desirudin.
Antithrombin Alfa The therapeutic efficacy of Formic acid can be decreased when used in combination with Antithrombin Alfa.
Protein C The therapeutic efficacy of Formic acid can be decreased when used in combination with Protein C.
Antithrombin III human The therapeutic efficacy of Formic acid can be decreased when used in combination with Antithrombin III human.
Letaxaban The therapeutic efficacy of Formic acid can be decreased when used in combination with Letaxaban.
Darexaban The therapeutic efficacy of Formic acid can be decreased when used in combination with Darexaban.
Betrixaban The therapeutic efficacy of Formic acid can be decreased when used in combination with Betrixaban.
Nafamostat The therapeutic efficacy of Formic acid can be decreased when used in combination with Nafamostat.
Gabexate The therapeutic efficacy of Formic acid can be decreased when used in combination with Gabexate.
Fluindione The therapeutic efficacy of Formic acid can be decreased when used in combination with Fluindione.
Protein S human The therapeutic efficacy of Formic acid can be decreased when used in combination with Protein S human.
Brinase The therapeutic efficacy of Formic acid can be decreased when used in combination with Brinase.
Clorindione The therapeutic efficacy of Formic acid can be decreased when used in combination with Clorindione.
Diphenadione The therapeutic efficacy of Formic acid can be decreased when used in combination with Diphenadione.
Tioclomarol The therapeutic efficacy of Formic acid can be decreased when used in combination with Tioclomarol.
Melagatran The therapeutic efficacy of Formic acid can be decreased when used in combination with Melagatran.
Saruplase The therapeutic efficacy of Formic acid can be decreased when used in combination with Saruplase.
(S)-Warfarin The therapeutic efficacy of Formic acid can be decreased when used in combination with (S)-Warfarin.
Tocopherylquinone The therapeutic efficacy of Formic acid can be decreased when used in combination with Tocopherylquinone.
Dabigatran The therapeutic efficacy of Formic acid can be decreased when used in combination with Dabigatran.
Semuloparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Semuloparin.
Troxerutin The therapeutic efficacy of Formic acid can be decreased when used in combination with Troxerutin.
Edetic acid The therapeutic efficacy of Formic acid can be decreased when used in combination with Edetic acid.
Reviparin The therapeutic efficacy of Formic acid can be decreased when used in combination with Reviparin.
Dermatan sulfate The therapeutic efficacy of Formic acid can be decreased when used in combination with Dermatan sulfate.
SR-123781A The therapeutic efficacy of Formic acid can be decreased when used in combination with SR-123781A.
Limaprost The therapeutic efficacy of Formic acid can be decreased when used in combination with Limaprost.

Target Protein

Nitric oxide synthase 1 NOS1
Hematopoietic prostaglandin D synthase HPGDS
Delta-aminolevulinic acid dehydratase ALAD
Peptide deformylase def
Hypoxanthine-guanine-xanthine phosphoribosyltransferase LACZ
Carbonic anhydrase 2 CA2
Heme oxygenase 1 HMOX1
Fibroblast growth factor 1 FGF1
Putative hydroxypyruvate isomerase YgbM ygbM
Delta-aminolevulinic acid dehydratase hemB
Ribonuclease pancreatic RNASE1
3-phosphoshikimate 1-carboxyvinyltransferase aroA
Subtilisin Carlsberg apr
Peptide deformylase def
Aminodeoxychorismate synthase component 1 pabB
Dihydroorotate dehydrogenase (quinone) pyrD
(S)-2-haloacid dehalogenase dhlB
Beta-lactamase OXA-2 bla
Catalase katA
Signal recognition particle protein ffh
Streptavidin
Methylglyoxal synthase mgsA
C-terminal-binding protein 1 CTBP1
6-phosphogluconolactonase pgl
Citrate lyase subunit beta-like protein citE
Peripheral plasma membrane protein CASK CASK
Guanylate kinase gmk
Probable butyrate kinase 2 buk2
Gamma-glutamylaminecyclotransferase GGACT
Parvalbumin alpha PVALB
Acylphosphatase-2 ACYP2
Uncharacterized protein
Arginine N-succinyltransferase subunit alpha astA
Putative mannose-6-phosphate isomerase YvyI yvyI
Mannoside ABC transport system, sugar-binding protein
Probable phosphatase YcdX ycdX
Oxalate decarboxylase OxdC oxdC
Putative ketoacyl reductase actIII
Gephyrin GPHN
Glyoxalase family protein
Cytohesin-2 CYTH2
Glutaconyl-CoA decarboxylase subunit alpha gcdA
Transcriptional regulator, IclR family
Catalase katA
Putative L-rhamnose mutarotase
Glutathione S-transferase GST
Hypoxanthine-guanine phosphoribosyltransferase HGPRTase
Glutaminase 1 glsA1
Glutaminase 1 glsA1
Molybdopterin synthase catalytic subunit moaE
Aminotransferase, putative
Iron ABC transporter substrate-binding protein fbpA
DNA gyrase subunit B gyrB
Phenazine biosynthesis protein PhzD phzD1

Referensi & Sumber

Synthesis reference: Gunter Roscher, Helmut Schaum, Heinz Schmitz, "Process for the preparation of practically formic acid-free acetic acid." U.S. Patent US4380663, issued August, 1944.

Contoh Produk & Brand

Produk: 11 • International brands: 0
Produk
  • Irospan 24/6
    Kit; Tablet; Tablet, film coated • - • Oral • US
  • NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA
    Capsule, gelatin coated; Kit; Tablet • - • Oral • US
  • NESTABS Prenatal Multi-vitamin/Mineral Supplement
    Tablet, film coated • - • Oral • US
  • Nutri-Tab OB
    Tablet • - • Oral • US
  • Nutri-Tab OB plus DHA
    Tablet • - • Oral • US
  • Pre-Tabs DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA
    Kit • - • Oral • US
  • Prenate DHA
    Capsule, gelatin coated • - • Oral • US
  • Prenate Elite
    Tablet, coated • - • Oral • US
Menampilkan 8 dari 11 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul